Aura Biosciences Inc Dossier - Source-backed chat

Aura Biosciences Inc

AURANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.59

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $6.28Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $651.3M

Enterprise Value $600.4M

Shares Outstanding 103.7M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Aura Biosciences is a clinical-stage biotechnology company uniquely positioned to revolutionize solid tumor therapy through its proprietary virus-like drug conjugate (VDC) platform. The company's lead candidate, belzupacap sarotalocan (bel-sar), targets early-stage choroidal melanoma, a rare and life-threatening eye cancer with no approved drug therapies. By utilizing light-activated local destruction, bel-sar aims to deliver tumor control while preserving vision and organ function, offering a highly differentiated alternative to radiotherapy. With the global Phase 3 CoMpass trial fully enrolled as of June 2026 and a robust cash runway extending into the second half of 2028 following a major public offering, Aura presents a compelling, de-risked investment opportunity in the precision oncology space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$18.80

High · most bullish analyst$24.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$4.0020%

The Phase 3 CoMpass trial fails to meet its primary endpoint or shows marginal efficacy compared to sham control, or safety concerns emerge regarding off-target toxicity. Platform expansion into bladder cancer fails to show meaningful clinical responses, severely limiting the company's valuation and forcing a reliance on dilutive capital raises as the cash runway depletes toward 2028.

Base CaseCentral scenario

$18.8050%

Matches the consensus mean

The Phase 3 CoMpass trial successfully completes and meets its primary endpoint in 2H 2027, demonstrating statistically significant tumor control and superior vision preservation compared to historical radiotherapy benchmarks. Bel-sar achieves regulatory approval in early choroidal melanoma, establishing a solid commercial foundation, while early-stage urologic oncology programs progress steadily.

Bull CaseUpside scenario

$24.0030%

The Phase 3 CoMpass trial meets its primary endpoint in 2H 2027 with exceptional vision-preservation and tumor-control data, leading to rapid FDA approval as a first-line standard of care. Simultaneously, positive readouts in NMIBC (bladder cancer) and choroidal metastases validate the platform's expansion into non-ocular solid tumors, attracting lucrative big-pharma partnerships or acquisition bids.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class VDC platform targeting high unmet needs in ocular and urologic oncology with organ-preserving precision.
Phase 3 CoMpass trial in early choroidal melanoma completed enrollment in June 2026, significantly de-risking clinical timelines.
Strong balance sheet with cash runway extending into 2H 2028 following the successful closing of a $299 million public offering in May 2026.
Fast Track and Orphan Drug designations from the FDA and EMA for bel-sar in early choroidal melanoma.
Experienced leadership transition with Natalie Holles appointed as CEO in April 2026, bringing extensive rare disease operational and commercialization expertise.

Key Investment Risks

Clinical development risk: reliance on a single lead asset (bel-sar) for near-term valuation.
Regulatory risk: potential delays or failure to secure FDA/EMA approvals for bel-sar.
Commercial adoption risk: competing against deeply entrenched radiotherapy referral pathways and physician habits.
Platform expansion risk: early-stage trials in bladder cancer and choroidal metastases may not replicate the efficacy seen in choroidal melanoma.

Thesis Invalidation Triggers

Failure of the Phase 3 CoMpass trial to meet its primary endpoint of tumor control or vision preservation in 2H 2027.
Severe adverse safety events or off-target toxicities identified in ongoing ocular or urologic clinical trials.
Significant delays in regulatory filings or refusal to file letters from the FDA/EMA.
Inability to demonstrate clinical efficacy in the Phase 1b/2 NMIBC trial, limiting the platform's expansion potential.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.